# Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis

> **NCT07207954** · PHASE1 · RECRUITING · sponsor: **Lifordi Immunotherapeutics, Inc.** · enrollment: 176 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** LFD-200
- **OTHER:** Placebo
- **DRUG:** Oral Prednisone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07207954
- **Lead sponsor:** Lifordi Immunotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-06
- **Primary completion:** 2027-07-16
- **Final completion:** 2027-07-16
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07207954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07207954, "Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07207954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*